ダウンロード数: 1113
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
56_203.pdf | 625.11 kB | Adobe PDF | 見る/開く |
タイトル: | ホルモン抵抗性前立腺癌に対する低用量Docetaxel, Estramustine, Dexamethasone 併用療法の検討 |
その他のタイトル: | Low-Dose Docetaxel, Estramustine and Dexamethasone Combination Chemotherapy for Hormone-Refractory Prostate Cancer |
著者: | 小林, 一樹 横西, 哲広 伊藤, 悠亮 松本, 達也 梅本, 晋 逢坂, 公人 中村, 昌史 小貫, 竜昭 小宮, 敦 大古, 美治 酒井, 直樹 野口, 純男 岸, 洋一 横溝, 由美子 河合, 正記 岡島, 和登 田尻, 雄大 藤川, 敦 太田, 純一 湯村, 寧 森山, 正敏 |
著者名の別形: | Kobayashi, Kazuki Yokonishi, Tetsuhiro Ito, Yusuke Matsumoto, Tatsuya Umemoto, Susumu Osaka, Kimito Nakamura, Masafumi Onuki, Tatsuaki Komiya, Atsushi Ohgo, Yoshiharu Sakai, Naoki Noguchi, Sumio Kishi, Hiroichi Yokomizo, Yumiko Kawai, Masaki Okajima, Kazuto Tajiri, Takehiro Fujikawa, Atsushi Ohta, Junichi Yumura, Yasushi Moriyama, Masatoshi |
キーワード: | Hormone-refractory prostate cancer Docetaxel Esutramustine Chemotherapy Dexamethazone |
発行日: | Apr-2010 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 56 |
号: | 4 |
開始ページ: | 203 |
終了ページ: | 207 |
抄録: | The objective of this study was to evaluate the efficacy and safety of low-dose docetaxel, estramustine and dexamethasone combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC). Sixty-nine patients with HRPC were enrolled. Docetaxel was given at a dose of 25 mg/m2 on days 1 and 8 every 3 weeks, oral estramustine 280 mg twice daily on days 1 to 3 and 8 to 10, and oral dexamethasone 1mg daily throughout the course. Cycles were repeated every 21 days. Treatment was continued until disease progression or excessive toxicity. Patients were evaluated for response and toxicity. Patients received a median of eleven cycles (range : 1-25). Prostatic-specific antigen (PSA) was decreased greater than 50% in 53 (77%) out of 69 patients and median duration of PSA response was 10.2 months. Median time to progression and overall survival 10.2 and 24 months, respectively. Grade 1-2 fatigue was the most common toxicity observed in 10 (15%) patients. Grade 3-4 toxicities were observed in five (7%) patients (2 thrombosis, 2 bilirubin elevation, and 1 aspartate transaminase/alanine transaminase elevation). Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy is an effective and well tolerated treatment for Japanese HRPC patients. |
著作権等: | 許諾条件により本文は2011-05-01に公開 |
URI: | http://hdl.handle.net/2433/109923 |
PubMed ID: | 20448443 |
出現コレクション: | Vol.56 No.4 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。